

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/534,003	05/05/2005	Nobuyuki Miyaki	271877US0PCT	1366
22850	7590 11/28/2005		EXAMINER	
OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C. 1940 DUKE STREET			TESKIN, FRED M	
	IA, VA 22314	ART UNIT	PAPER NUMBER	
	•		1713	

DATE MAILED: 11/28/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
_		10/534,003	MIYAKI ET AL.			
	Office Action Summary	Examiner	Art Unit			
		Fred M. Teskin	1713			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SH WHIC - Exter after - If NO - Failu Any I	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DANSIONS of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. Period for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION (36(a). In no event, however, may a reply be will apply and will expire SIX (6) MONTHS from cause the application to become ABANDON	ON. timely filed om the mailing date of this communication. NED (35 U.S.C. § 133).			
Status						
1)□ 2a)□ 3)□	Responsive to communication(s) filed on This action is FINAL . 2b) This Since this application is in condition for allowar closed in accordance with the practice under E	action is non-final. nce except for formal matters, p				
Dispositi	on of Claims					
5)□ 6)⊠ 7)⊠ 8)□ Applicati 9)□ 10)□	Claim(s) 1-8 is/are pending in the application. 4a) Of the above claim(s) is/are withdraw Claim(s) is/are allowed. Claim(s) 1-4 is/are rejected. Claim(s) 5-8 is/are objected to. Claim(s) are subject to restriction and/or on Papers The specification is objected to by the Examine The drawing(s) filed on is/are: a) acceeded a possible of the correction and or on the correction of the correction o	r election requirement. r. epted or b) objected to by the drawing(s) be held in abeyance. So is required if the drawing(s) is consistent or so is required if the drawing(s) is consistent or so is required if the drawing(s) is consistent or so is required if the drawing(s) is consistent or so is required if the drawing(s) is consistent or so is required if the drawing(s) is consistent or so is required if the drawing(s) is consistent or so is required if the drawing(s) is consistent or so is required if the drawing(s) is consistent or so is required.	Gee 37 CFR 1.85(a). Objected to. See 37 CFR 1.121(d).			
Priority ເ	ınder 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
2) 🔲 Notice 3) 🔯 Inform	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) No(s)/Mail Date 071405	4) Interview Summa Paper No(s)/Mail 5) Notice of Informal 6) Other:				

Art Unit: 1713

Claims 1-8 are currently pending and under examination.

The abstract of the disclosure is objected to because of undue length. Correction is required. See MPEP § 608.01(b)(C).

The disclosure is objected to because of the following informalities: a clerical error is noted on page 41, line 7: "dibromdie" should read –dibromide-. Appropriate correction of the specification is required.

Claims 5-8 are objected to under 37 CFR 1.75(c) as being in improper form because a multiple dependent claim cannot depend from any other multiple dependent claim. See MPEP § 608.01(n). Accordingly, claims 5-8 have not been further treated on the merits.

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Art Unit: 1713

Claim 1 is rejected under 35 U.S.C. 102(b) as being anticipated by US 3959234 to Kurosawa et al (hereinafter "Kurosawa").

Claim 1 is drawn to a ring-opened polynorbornene comprising a structural unit (I) represented by the general formula (I), wherein X^1 means an ethylene or vinylene group and R^3 represents a group represented by the general formulae (I-1) or (I-2).

Per the recited formulae (I) and (I-1), the claim is considered readable on ringopened polynorbornene homopolymer comprising a structural unit wherein X¹ is ethylene, R¹ and R² are hydrogen and R³ is phenyl. Such a ring-opened polynorbornene homopolymer is described in numerous working examples of Kurosawa. Thus, Examples 12-16 and 19-21 detail the ring-opening polymerization of N-phenyl-3,6-methylene-1,2,3,6-tetrahydro-phthalimide, a species of Kurosawa's "Atype" imide type norbornene derivative which corresponds to general formula (II) in column 3, line 55, with R being phenyl. As this norbornene derivative is identical to the applicants' monomer (1) as shown on page 21 of their specification and is subjected to the same chemical reaction (ring-opening polymerization), it follows that the resultant polymer will necessarily comprise a structural unit conforming to general formulae (I) and (I-1) as claimed. Indeed, the ring-opening reaction illustrated at column 13, lines 35+ of Kurosawa depicts a polymeric structural unit meeting the terms of claim 1 when X^{1} and R^{3} are ethylene and phenyl, respectively; R^{1} and R^{2} are hydrogen and m = n = 0in general formula (I).

The description in Kurosawa of specific embodiments of the subject matter broadly claimed in claim 1 constitutes a description of the invention for anticipation purposes. See In re Luckach, 169 USPQ 795 (CCPA 1971).

Claims 2-4 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kurosawa.

Kurosawa is applied as in the preceding rejection. It would have been obvious to one of ordinary skill in the art to modify the homopolymer products of any of the above-cited examples through copolymerization so as to provide a structural unit (II) as per claims 2-4, given Kurosawa's expressed preference to "carry out the ring-opening polymerization of a mixture of imide type norbornene derivatives and other cycloolefins with the latter used at the rate of 1.0 mol at most based on 1 mol of the former."

(Column 12, final line to column 13, line 4; italics added.) The "other cycloolefins" contemplated by Kurosawa include specific chemical species which, in ring-opened form, correspond to general formula (II) (representing structural unit (II)) as set out in claim 2; e.g., norbornene and various norbornene derivatives as listed in column 11, lines 47+ and column 12, lines 64-67.

The prior art made of record and not relied upon is considered pertinent to applicants' disclosure.

Kokuryo et al is cited as further evidence of the conventionality of ring-opening polymerization products (homopolymer and interpolymer) of norbornene derivatives

Art Unit: 1713

containing at least one N-substituted cyclic imide group, wherein the imide nitrogen substituent is selected from, *inter alia*, aryl radicals and alkyl-substituted aryl radicals of specified carbon atom numbers (note col. 2, II. 40-45 and col. 10, II. 35-60).

No claims are allowed.

Any inquiry concerning this communication should be directed to Examiner F. M. Teskin whose telephone number is (571) 272-1116. The examiner can normally be reached on Monday through Thursday from 7:00 AM - 4:30 PM, and can also be reached on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, David Wu, can be reached on (571) 272-1114. The appropriate fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

FRED TESKIN
PRIMARY EXAMINER

FMTeskin/11-13-05